ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Ohr Pharmaceutical, Inc." (OHRP) Report Updated: May 23, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Ohr Pharmaceutical, Inc." (OHRP)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Biotechnology
Competitors: EBS,LOXO,AVXL,FPRX

Stock Analysis

Rating: Monthly View

A
B
C
D
F
May June July August September October November December January February March April

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

"Ohr Pharmaceutical, Inc."© quotemedia

Company Profile

OHR Pharmaceutical, Inc., a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is OHR-102 eye drops, a novel therapeutic product, which could provide a non-invasive therapy to enhance vision outcomes. The company is evaluating OHR-102 eye drops, which completed Phase II clinical trials for the treatment of retinal diseases, including wet-AMD, retinal vein occlusion, and proliferative diabetic retinopathy. Its preclinical pipeline of sustained release programs include sustained release formulations of small molecule and protein therapeutics for the treatment of ocular diseases, such as steroid induced glaucoma, allergies, and retinal disease. OHR Pharmaceutical, Inc. is headquartered in New York, New York.